<DOC>
	<DOC>NCT00191295</DOC>
	<brief_summary>Atomoxetine versus placebo in Children with Attention-Deficit/Hyperactivity Disorder (ADHD)</brief_summary>
	<brief_title>Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD)</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Patients are diagnosed with ADHD Patients must be able to swallow capsules Patients must be of normal intelligence Patients who weigh less than 15 kg or more than 75 kg Patients with organic brain disease (for example, dementia or traumatic brain injury residual)</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>